Correspondence sent from Tom Jefferson to the European Medicines Agency on 3 December 2012.
Displaying 1-4 out of 4 published
EMA responds to Jefferson's email dated 12th of February 2013
Competing interests: assessed tamiflu for regulatory purposes
Europe, London
Click to like:
19 February 2013
Tom Jefferson responds to the letter from the EMA (below). He believes it shows that they are not comfortable taking a strong position with respect to Tamiflu's effect on risk of complications, though it does not appear that they have carried out their own analysis to confirm the fact, and are accepting Roche's analysis at face value. This reply requests more documentation regarding this from the EMA.
They do however state unambiguously that Roche's clinical trial does not show that Tamiflu reduces transmission as has been claimed in the past.
Competing interests: None declared
Cochrane Vaccines Field, Rome
Click to like:
11
+Vote up!
18 February 2013
The EMA responds to Jefferson's query.
Competing interests: None declared
European Medicines Agency, London
Click to like:
10
+Vote up!
In the letter, Jefferson explains that the points the Cochrane Collaboration would like to discuss are the effects of Tamiflu both in the treatment and post exposure prophylaxis (PEP) of influenza as well as the drug’s mode of action.
Competing interests: None declared
The Cochrane Collaboration, Rome
Click to like:
45
+Vote up!
Latest comments and most commented
Re: Better management of patients with multimorbidity
Published 17 May 2013
Re: India must raise the status of primary care
Published 17 May 2013
Re: Partnering with patients
Published 17 May 2013
Re: Rescue boards are set up in England to deal with “significant deterioration” in A&E departments
Published 17 May 2013